Chiome Bioscience Inc (4583)

Tokyo
Currency in JPY
258.0
+17.0(+7.05%)
Closed
4583 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Earnings results expected in 5 days
Fair Value
Day's Range
239.0258.0
52 wk Range
75.0304.0
Key Statistics
Edit
Bid/Ask
257.00 / 258.00
Prev. Close
241
Open
242
Day's Range
239-258
52 wk Range
75-304
Volume
4.73M
Average Volume (3m)
12.73M
1-Year Change
86.96%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4583 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year
Show more

Chiome Bioscience Inc Company Profile

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. The company also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody production; and antibody generation services using the ADLib system. Its product pipeline under Phase 1 trial comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer (TNBC). The company’s product pipeline under preclinical study includes PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC; BMAA, an anti-semphorin3a antibody for treating renal and other diseases; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis; and PXLR, an anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. It serves universities, research institutions, diagnostic companies, and pharmaceutical companies. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.

Compare 4583 to Peers and Sector

Metrics to compare
4583
Peers
Sector
Relationship
P/E Ratio
−14.2x−2.9x−0.6x
PEG Ratio
0.79−0.140.00
Price/Book
14.2x2.1x2.6x
Price / LTM Sales
29.7x2.7x3.1x
Upside (Analyst Target)
-44.1%52.1%
Fair Value Upside
Unlock24.3%8.2%Unlock

Earnings

Latest Release
Nov 12, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Chiome Bioscience (4583) Stock Price Today?

The Chiome Bioscience stock price today is 258.00

What Stock Exchange Does Chiome Bioscience Trade On?

Chiome Bioscience is listed and trades on the Tokyo stock exchange.

What Is the Stock Symbol for Chiome Bioscience?

The stock symbol for Chiome Bioscience is "4583."

What Is the Chiome Bioscience Market Cap?

As of today, Chiome Bioscience market cap is 17.28B.

What is Chiome Bioscience Earnings Per Share?

The Chiome Bioscience EPS is -27.70.

What Is the Next Chiome Bioscience Earnings Date?

Chiome Bioscience will release its next earnings report on 12 Feb 2025.

From a Technical Analysis Perspective, Is 4583 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.